PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

May 28, 2020

Kellsye P Fabian1, Michelle R Padget1, Renee N. Donahue1, Kristen Solocinski1, Yvette Robbins1, Clint T. Allen2, John H. Lee3, Shahrooz Rabizadeh4,5, Patrick Soon-Shiong4,5, http://orcid.org/0000-0001-7932-4072Jeffrey Schlom1 and http://orcid.org/0000-0001-5282-3154James W Hodge1
Author affiliations

Contact us at


How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious disease severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Immunotherapies and cell therapies are key to future cancer treatments. Our investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.